5-Formylpyrazine-2-carboxamide | 1824146-81-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-Formylpyrazine-2-carboxamide
• CAS: 1824146-81-7
• 化学式: C₆H₅N₃O₂
• 分子量: 151.12
• InChiKey: PZIYKCYGMAJUGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  85.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders
  申请人：Chen L. Yuhpyng

  公开号：US20050107381A1

  公开（公告）日：2005-05-19

  The present invention relates to compounds of the Formula wherein R 1 , R 1a , R 1b , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , X, Y, W, U, Z, m and n are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. This invention also relates to pharmaceutical compositions and methods of treating diseases, for example, neurodegenerative diseases, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.

  本发明涉及公式I的化合物，其中R1，R1a，R1b，R2，R3，R4，R5，R6，R7，R8，R9，R10，R11，R12，X，Y，W，U，Z，m和n如所定义。公式I的化合物具有抑制Aβ肽生成活性。本发明还涉及含有公式I化合物的制药组合物和治疗疾病的方法，例如神经退行性疾病，例如阿尔茨海默病，在哺乳动物中治疗。
• Process to obtain dimers, trimers and up to polymers from pyridinemethanol derivatives compounds
  申请人：Benemerita Universidad Autonoma de Puebla

  公开号：EP2025697A1

  公开（公告）日：2009-02-18

  The process of the current invention, named Percino-Chapela, has as one of its main novelty features that starting from pyridinmethanol derivatives, a dimerization or polymerization reaction of pyridinic alcohols is carried out in order to produce novel products, the process of the current invention has the following aspects that characterize it: it is carried out in the absence or presence of some solvent, during the process of the current invention, temperature may be or may be not used as catalyst, in the process of the current invention the reaction may be or may not be catalyzed by the presence of a catalyst (acid or base), the resultant products can be produced and separated in an easy way, in the process of the current invention starting from pyridinic alcohols the resultant ethenediols can be produced by a single step reaction, the pyridinmethanol derivatives used as starting compounds, do not oxidize as easily and their handling is easier than that of other compounds previously used that oxidize easily, the products produced with etheneidol parts can be used as antioxidants due to their capacity to act as free radicals scavengers.

  本发明的工艺名为 Percino-Chapela，其主要新颖特征之一是从吡啶甲醇衍生物开始，进行吡啶醇的二聚或聚合反应，以生产新产品：在本发明的工艺过程中，可以使用或不使用温度作为催化剂；在本发明的工艺过程中，可以使用或不使用催化剂（酸或碱）来催化反应；可以方便地生产和分离生成物、在本发明的工艺中，从吡啶醇开始，可以通过一步反应生产出乙烯二醇，用作起始化合物的吡啶甲醇衍生物不容易氧化，与以前使用的其他容易氧化的化合物相比，处理起来更容易，用乙烯二醇部分生产的产品可以用作抗氧化剂，因为它们具有清除自由基的能力。
• 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
  申请人：Pfizer Products Inc.

  公开号：EP1654260A2

  公开（公告）日：2006-05-10
• EP1654260A4
  申请人：——

  公开号：EP1654260A4

  公开（公告）日：2008-09-24
• INHIBITORS OF APOL1 AND METHODS OF USING SAME
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20220106327A1

  公开（公告）日：2022-04-07

  The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).